Emergent BioSolutions Inc.
Close on Oct 19, 2026
- Market cap
- $328.18M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 28, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | After market close | $234.30M | $-3.49 | $0.60 |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 30, 2026 | After market close | $156.10M | $0.07 | $0.21 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | After market close | $148.70M | $-1.04 | $-0.43 |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 29, 2025 | After market close | $231.10M | $0.91 | $1.06 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | After market close | $140.90M | $-0.22 | $0.16 |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | After market close | $222.20M | $1.19 | $0.71 |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 3, 2025 | After market close | $194.70M | $-0.58 | $0.05 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | After market close | $293.80M | $2.06 | $1.37 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | After market close | $254.70M | $-5.38 | $-2.32 |
| Q1 FY2024 Ended Mar 31, 2024 | May 1, 2024 | After market close | $300.40M | $0.17 | $0.59 |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 6, 2024 | After market close | $276.60M | $-0.95 | $-0.77 |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Capex | full year 2026 | $17.00M | Maintained |
| Adjusted EBITDAnon-GAAP | full year 2026 | $130.00M to $150.00M | Lowered |
| Gross margin %GAAP | 2026 Full Year | 32% to 35% | Lowered |
| Adjusted gross margin %non-GAAP | full year 2026 | 42% to 44% | Lowered |
| Weighted avg. fully diluted share count | full year 2026 | 52 | New |
| R&D | full year 2026 | 6% | New |
| SG&A | full year 2026 | 27% to 28% | Raised |
| Interest expense | full year 2026 | $40.00M | New |
| Stock-based compensation expense | full year 2026 | $19.00M | Lowered |
| Depreciation & amortization | full year 2026 | $82.00M | Raised |
| Net lossGAAP | full year 2026 | -$245.00M to -$225.00M | Lowered |
| Adjusted net incomenon-GAAP | full year 2026 | $10.00M to $30.00M | Lowered |
| Total revenues | full year 2026 | $645.00M to $675.00M | Lowered |
| Total revenues | Q3 2026 | $110.00M to $130.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Emergent BioSolutions filed with the SEC
EMERGENT BIOSOLUTIONS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
Results of operations · Exit or restructuring costs · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
1 August 5, 2026 2026 Second Quarter Financial Results Our Mission: Protect and Save Lives
Results of operations · Exit or restructuring costs · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
1 April 30, 2026 2026 First Quarter Financial Results Our Mission: Protect and Save Lives
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility
Material agreement · Agreement terminated · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EMERGENT BIOSO LUTIONS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
6 2025 Business Performance & Key Highlights Joe Papa President and Chief Executive Officer 6
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
World th 44 Annual J.P. Morgan Healthcare Conference Joe Papa President and Chief Executive Officer January 14, 2026 1 1
Regulation FD disclosure · EX-99.1 to Form 8-K
Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation
Regulation FD disclosure · EX-99.1 to Form 8-K
Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site
Regulation FD disclosure · EX-99.1 to Form 8-K
Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EMERGENT BIOSO LUTIONS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
4 4 Our Leadership in Public Health Joe Papa President and Chief Executive Officer
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
EMERGENT BIOSO LUTIONS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
IN RE EMERGENT BIOSOLUTIONS INC.,
Other events · EX-99.1 to Form 8-K
IN RE EMERGENT BIOSOLUTIONS INC.,
Other events · EX-99.2 to Form 8-K
EMERGENT BIOSO LUTIONS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Welcome Financials 8 Rich Lindahl EVP, Chief Financial Officer & Treasurer
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Emergent BioSolutions Announces Stock Repurchase Program
Other events · EX-99.1 to Form 8-K
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
Other events · EX-99.1 to Form 8-K
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EMERGENT BIOSO LUTIONS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
18 2025 Business Outlook & Catalysts to Enable Growth Joe Papa President and Chief Executive Officer
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
January 15, 2025 43rd Annual J.P.
Regulation FD disclosure · EX-99.1 to Form 8-K
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO ® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
Other events · EX-99.1 to Form 8-K
EMERGENT BIOSO LUTIONS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q3 2024 Financial Results Update November 6, 2024 Proprietary & Confidential
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility
Material agreement · Results of operations · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile
Material agreement · Agreement terminated · New financial obligation · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K